The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties

Diana Blank-Porat; Tal Gruss-Fischer; Nataly Tarasenko; Zvi Malik; Abraham Nudelman; Ada Rephaeli

doi:10.1016/j.canlet.2007.05.011

The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties

Diana Blank-Porat
, Tal Gruss-Fischer
, Nataly Tarasenko
, Zvi Malik
, Abraham Nudelman
, Ada Rephaeli

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

The antiangiogenic and antineoplastic activities of the butyric acid prodrugs AN-7 and AN-9 were demonstrated in vitro with HUVEC by inhibition of proliferation and vascular tubes formation, enhanced apoptosis, and inhibition of 22Rv-1 cells migration. In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1α, HER-2/neu, bFGF and increased PTEN level. AN-7 and AN-9 reduced hemoglobin accumulation in matrigel plugs implanted sc in Balb-c mice. Herein, we show that the anticancer activity of AN-7 and AN-9 can be attributed in part to their antiangiogenic activities suggesting potential therapeutic benefits for prostate cancer patients.

Original language	English
Pages (from-to)	39-48
Number of pages	10
Journal	Cancer Letters
Volume	256
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2007.05.011
State	Published - 18 Oct 2007

Bibliographical note

Funding Information:
This work was supported in part by grants from: CaPCURE Israel, Israeli Cancer Association (A.R.), Ministry of Commerce and Industry and Teva Pharmaceutical Industry Ltd. (A.N. and A.R.); Fellowships from the Ministry of Absorption in Science (N.T.) and The Marcus Center for Pharmaceutical and Medicinal Chemistry at Bar Ilan University (A.N.).

Funding

This work was supported in part by grants from: CaPCURE Israel, Israeli Cancer Association (A.R.), Ministry of Commerce and Industry and Teva Pharmaceutical Industry Ltd. (A.N. and A.R.); Fellowships from the Ministry of Absorption in Science (N.T.) and The Marcus Center for Pharmaceutical and Medicinal Chemistry at Bar Ilan University (A.N.).

Funders
Israeli Cancer Association
Marcus Center for Pharmaceutical and Medicinal Chemistry at Bar Ilan University
Ministry of Absorption in Science
Ministry of Commerce and Industry and Teva Pharmaceutical Industry Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Angiogenesis
Butyric acid prodrugs
Prostate carcinoma

Access to Document

10.1016/j.canlet.2007.05.011

Cite this

@article{ddf2784cdfe64e3985d4295126636693,

title = "The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties",

abstract = "The antiangiogenic and antineoplastic activities of the butyric acid prodrugs AN-7 and AN-9 were demonstrated in vitro with HUVEC by inhibition of proliferation and vascular tubes formation, enhanced apoptosis, and inhibition of 22Rv-1 cells migration. In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1α, HER-2/neu, bFGF and increased PTEN level. AN-7 and AN-9 reduced hemoglobin accumulation in matrigel plugs implanted sc in Balb-c mice. Herein, we show that the anticancer activity of AN-7 and AN-9 can be attributed in part to their antiangiogenic activities suggesting potential therapeutic benefits for prostate cancer patients.",

keywords = "Angiogenesis, Butyric acid prodrugs, Prostate carcinoma",

author = "Diana Blank-Porat and Tal Gruss-Fischer and Nataly Tarasenko and Zvi Malik and Abraham Nudelman and Ada Rephaeli",

note = "Funding Information: This work was supported in part by grants from: CaPCURE Israel, Israeli Cancer Association (A.R.), Ministry of Commerce and Industry and Teva Pharmaceutical Industry Ltd. (A.N. and A.R.); Fellowships from the Ministry of Absorption in Science (N.T.) and The Marcus Center for Pharmaceutical and Medicinal Chemistry at Bar Ilan University (A.N.).",

year = "2007",

month = oct,

day = "18",

doi = "10.1016/j.canlet.2007.05.011",

language = "אנגלית",

volume = "256",

pages = "39--48",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties

AU - Blank-Porat, Diana

AU - Gruss-Fischer, Tal

AU - Tarasenko, Nataly

AU - Malik, Zvi

AU - Nudelman, Abraham

AU - Rephaeli, Ada

N1 - Funding Information: This work was supported in part by grants from: CaPCURE Israel, Israeli Cancer Association (A.R.), Ministry of Commerce and Industry and Teva Pharmaceutical Industry Ltd. (A.N. and A.R.); Fellowships from the Ministry of Absorption in Science (N.T.) and The Marcus Center for Pharmaceutical and Medicinal Chemistry at Bar Ilan University (A.N.).

PY - 2007/10/18

Y1 - 2007/10/18

N2 - The antiangiogenic and antineoplastic activities of the butyric acid prodrugs AN-7 and AN-9 were demonstrated in vitro with HUVEC by inhibition of proliferation and vascular tubes formation, enhanced apoptosis, and inhibition of 22Rv-1 cells migration. In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1α, HER-2/neu, bFGF and increased PTEN level. AN-7 and AN-9 reduced hemoglobin accumulation in matrigel plugs implanted sc in Balb-c mice. Herein, we show that the anticancer activity of AN-7 and AN-9 can be attributed in part to their antiangiogenic activities suggesting potential therapeutic benefits for prostate cancer patients.

AB - The antiangiogenic and antineoplastic activities of the butyric acid prodrugs AN-7 and AN-9 were demonstrated in vitro with HUVEC by inhibition of proliferation and vascular tubes formation, enhanced apoptosis, and inhibition of 22Rv-1 cells migration. In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1α, HER-2/neu, bFGF and increased PTEN level. AN-7 and AN-9 reduced hemoglobin accumulation in matrigel plugs implanted sc in Balb-c mice. Herein, we show that the anticancer activity of AN-7 and AN-9 can be attributed in part to their antiangiogenic activities suggesting potential therapeutic benefits for prostate cancer patients.

KW - Angiogenesis

KW - Butyric acid prodrugs

KW - Prostate carcinoma

UR - https://www.scopus.com/pages/publications/34548287904

U2 - 10.1016/j.canlet.2007.05.011

DO - 10.1016/j.canlet.2007.05.011

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17611019

AN - SCOPUS:34548287904

SN - 0304-3835

VL - 256

SP - 39

EP - 48

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this